AVTX
Income statement / Annual
Last year (2024), Avalo Therapeutics, Inc.'s total revenue was $441,000.00,
a decrease of 77.08% from the previous year.
In 2024, Avalo Therapeutics, Inc.'s net income was -$35.13 M.
See Avalo Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$441,000.00 |
$1.92 M |
$18.05 M |
$5.40 M |
$6.70 M |
$6.75 M |
$18.33 M |
$27.81 M |
$1.15 M |
$0.00 |
| Cost of Revenue |
$27.28 M
|
$1.28 M
|
$3.43 M
|
$1.49 M
|
$300,000.00
|
$11.63 M
|
$7.48 M
|
$635,648.00
|
$8.24 M
|
$23,508.00
|
| Gross Profit |
-$26.83 M
|
$640,000.00
|
$14.62 M
|
$3.91 M
|
$6.40 M
|
-$4.88 M
|
$10.85 M
|
$27.18 M
|
-$7.09 M
|
-$23,508.00
|
| Gross Profit Ratio |
-60.85
|
0.33
|
0.81
|
0.72
|
0.96
|
-0.72
|
0.59
|
0.98
|
-6.15
|
0
|
| Research and Development Expenses |
$24.44 M
|
$13.78 M
|
$31.31 M
|
$59.84 M
|
$32.19 M
|
$11.76 M
|
$5.79 M
|
$4.37 M
|
$10.15 M
|
$6.59 M
|
| General & Administrative Expenses |
$17.24 M
|
$10.27 M
|
$20.64 M
|
$21.83 M
|
$17.42 M
|
$10.12 M
|
$10.68 M
|
$7.94 M
|
$7.08 M
|
$4.42 M
|
| Selling & Marketing Expenses |
$0.00
|
$33,000.00
|
$76,000.00
|
$2.83 M
|
$2.34 M
|
$1.48 M
|
$8.52 M
|
$973,345.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$17.24 M
|
$10.30 M
|
$20.71 M
|
$24.66 M
|
$19.76 M
|
$11.61 M
|
$19.20 M
|
$8.91 M
|
$7.08 M
|
$4.42 M
|
| Other Expenses |
$0.00
|
-$23.44 M
|
$38,000.00
|
$1.55 M
|
$1.74 M
|
$1.34 M
|
$13,657.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$41.68 M
|
$640,000.00
|
$52.06 M
|
$86.04 M
|
$53.69 M
|
$24.71 M
|
$29.52 M
|
$13.29 M
|
$17.23 M
|
$11.01 M
|
| Cost And Expenses |
$68.95 M
|
$25.37 M
|
$55.49 M
|
$87.53 M
|
$53.99 M
|
$24.14 M
|
$37.00 M
|
$13.92 M
|
$17.23 M
|
$11.01 M
|
| Interest Income |
$0.00
|
$0.00
|
$4.17 M
|
$2.39 M
|
$49,000.00
|
$121,326.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$3.32 M
|
$3.42 M
|
$4.17 M
|
$2.39 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$793,205.00
|
| Depreciation & Amortization |
$0.00
|
$158,000.00
|
$166,000.00
|
$1.66 M
|
$1.84 M
|
$1.46 M
|
$1.85 M
|
$425,476.00
|
$26,856.00
|
$23,508.00
|
| EBITDA |
-$68.51 M |
-$27.96 M |
-$37.29 M |
-$80.50 M |
-$45.45 M |
-$17.36 M |
-$13.07 M |
$14.35 M |
-$16.05 M |
-$10.46 M |
| EBITDA Ratio |
-155.36
|
-14.53
|
-2.07
|
-14.93
|
-3.76
|
-2.57
|
0.35
|
0.52
|
-14.01
|
0
|
| Operating Income Ratio |
-155.36
|
-12.19
|
-2.07
|
-15.22
|
-4.02
|
-2.58
|
-2.15
|
0.5
|
-13.95
|
0
|
| Total Other Income/Expenses Net |
$33.50 M
|
-$8.09 M
|
-$4.19 M
|
-$2.41 M
|
$5.67 M
|
$12.26 M
|
$54,928.00
|
-$53,640.00
|
-$391,556.00
|
$519,844.00
|
| Income Before Tax |
-$35.02 M
|
-$31.53 M
|
-$41.63 M
|
-$84.55 M
|
-$67.18 M
|
-$15.99 M
|
-$40.09 M
|
$13.84 M
|
-$16.47 M
|
-$10.49 M
|
| Income Before Tax Ratio |
-79.4
|
-16.39
|
-2.31
|
-15.66
|
-10.03
|
-2.37
|
-2.19
|
0.5
|
-14.29
|
0
|
| Income Tax Expense |
$114,000.00
|
$14,000.00
|
$28,000.00
|
-$196,000.00
|
-$2.79 M
|
$280,000.00
|
-$33,910.00
|
$1.97 M
|
$364,144.00
|
-$543,508.00
|
| Net Income |
-$35.13 M
|
-$31.54 M
|
-$41.66 M
|
-$84.35 M
|
-$64.38 M
|
-$16.27 M
|
-$40.05 M
|
$11.87 M
|
-$16.47 M
|
-$10.49 M
|
| Net Income Ratio |
-79.66
|
-16.4
|
-2.31
|
-15.63
|
-9.61
|
-2.41
|
-2.19
|
0.43
|
-14.29
|
0
|
| EPS |
-4.32 |
-113.58 |
-1062.65 |
-2330.66 |
-2523.77 |
-819.74 |
-3317.28 |
1856.88 |
-21.93 |
-16.21 |
| EPS Diluted |
-3.26 |
-113.58 |
-1062.65 |
-2330.66 |
-2523.77 |
-819.74 |
-3317.28 |
1822.74 |
-21.93 |
-16.21 |
| Weighted Average Shares Out |
$8.13 M
|
$277,727.00
|
$39,202.00
|
$36,191.00
|
$25,511.00
|
$19,849.00
|
$12,074.00
|
$6,392.36
|
$3,066.11
|
$772.92
|
| Weighted Average Shares Out Diluted |
$10.78 M
|
$277,727.00
|
$39,202.00
|
$36,191.00
|
$25,511.00
|
$19,849.00
|
$12,074.00
|
$6,512.08
|
$3,066.11
|
$772.92
|
| Link |
|
|
|
|
|
|
|
|
|
|
